GLP-1s, Pregnancy, Fertility and Breastfeeding: What the Labels Say

Planning pregnancy, avoiding pregnancy and breastfeeding are three different clinical situations. Each deserves a specific plan with the clinician treating the underlying condition and, when relevant, your obstetric or reproductive-health team. A general claim about GLP-1s cannot supply all three answers.

Start by identifying the exact medicine, formulation and reason for treatment. Semaglutide and tirzepatide instructions are not interchangeable, and information about an injection does not automatically apply to a tablet.

Are GLP-1s fertility treatments?

GLP-1 medicines are not approved specifically to treat infertility. The international PCOS guideline supports considering certain anti-obesity medicines for weight management in adults who meet general criteria; that is not a recommendation to use them as fertility drugs³. Improvement in a metabolic measure does not establish a predictable pregnancy benefit for an individual.

Our PCOS and PMOS guide explains where weight-management treatment fits in broader care. If pregnancy is the goal, ask which part of the plan addresses reproductive concerns, what assessment is needed and who coordinates the timing. Avoid treating reports of a “GLP-1 baby boom” as a treatment protocol or a reason to skip fertility care.

Tirzepatide has a specific birth-control instruction

Zepbound's August 2026 U.S. label advises people using oral hormonal contraception to switch to a non-oral method or add a barrier method for four weeks after starting and for four weeks after every dose increase². The instruction concerns delayed gastric emptying. It is not conditional on experiencing vomiting, diarrhea or noticeable nausea.

Do not turn that product-specific warning into a claim that all GLP-1s make every contraceptive pill unreliable. Vomiting or severe diarrhea can also raise separate questions about a pill's instructions. Ask a prescriber or pharmacist about your exact products and circumstances. Our birth-control interaction guide separates those issues.

Before a dose change, confirm the dates and the contraception plan in advance. If you think a contraceptive lapse has occurred, seek timely advice rather than waiting for the next weight-management visit. A customer-support message about billing is not a substitute for clinical advice about pregnancy prevention.

Semaglutide: plan using months, not an assumed eight-week rule

For Wegovy used for weight reduction or cardiovascular risk reduction, the June 2026 label specifies discontinuation at least two months before a planned pregnancy because semaglutide remains in the body for a long time¹. Two calendar months and eight weeks should not be treated as identical instructions.

Agree on an actual date with your prescriber and discuss what manages the original condition during the transition. Do not simply calculate a date from an article and leave diabetes or another condition without a care plan. Bring your medication list to the preconception appointment, including prescriptions from other services.

Tirzepatide: do not borrow Wegovy's interval

The current U.S. Zepbound label directs discontinuation when pregnancy is recognized, but does not establish an eight-week preconception interval². Your clinician should plan timing before you try to conceive instead of transferring semaglutide instructions to tirzepatide.

MotherToBaby explains that most tirzepatide can take around 30 days on average to leave the body in healthy adults, with individual variation⁴. That pharmacokinetic estimate is not a guarantee of pregnancy safety or a universal personal washout instruction. Ask which recommendation your clinician is using and how it fits your diagnosis and plans.

What if pregnancy happens during treatment?

Contact your prescribing and pregnancy-care clinicians promptly with the medicine name, formulation, dates and doses. Wegovy weight-management labeling and Zepbound labeling instruct discontinuation when pregnancy is recognized¹². The clinical team should also address treatment of the underlying condition.

Exposure does not tell a website what will happen to an individual pregnancy. MotherToBaby describes substantial limits in human tirzepatide pregnancy data⁴. Ask your clinicians what follow-up is appropriate and whether a pregnancy-exposure registry is relevant. Do not interpret the absence of complete data as either proof of harm or proof of safety.

Breastfeeding: formulation matters, but it is not the whole answer

Wegovy labeling recommends against breastfeeding during treatment with its oral tablets because of the SNAC absorption enhancer and possible infant accumulation. For the injection, the label describes missing data on milk transfer, infant effects and milk production and calls for weighing breastfeeding benefits, maternal need and potential risks¹. The absence of SNAC does not establish that the injection is safe for every breastfeeding parent and infant.

Zepbound's label reports low or undetectable milk concentrations after a single dose, while noting missing data on effects in breastfed infants and milk production². A single-dose milk finding does not resolve the full question of repeated treatment while nursing.

Discuss the exact product, the infant's situation and your treatment needs with the relevant clinicians. If comparing oral and injectable semaglutide, do not let convenience or price decide a clinical question that remains unsettled.

Leave the appointment with a coordinated plan

Ask for the contraception arrangements, any preconception stop date, the alternative treatment plan and the follow-up contact in writing. If more than one practice is involved, confirm who shares records and who handles a new pregnancy or breastfeeding question.

The provider-selection guide explains general service questions. A weight-management subscription cannot be assumed to provide fertility, obstetric or lactation care. Establish that care first and compare program terms only after the treatment plan is appropriate.